Latest news with #BTK
Yahoo
2 days ago
- Business
- Yahoo
Ascentage Pharma's Novel Cancer Drug Approved in China
Ascentage Pharma Group International (NASDAQ:AAPG) is one of the best young stocks to buy and hold for 5 years. On July 10, Ascentage Pharma announced that China's National Medical Products Administration/NMPA approved its novel Bcl-2 selective inhibitor, called lisaftoclax (APG-2575). It treats adult patients with chronic lymphocytic leukemia/CLL and small lymphocytic lymphoma/SLL, particularly those who have previously received at least one systemic therapy, which includes Bruton's tyrosine kinase (BTK) inhibitors. Lisaftoclax is the first Bcl-2 inhibitor to receive conditional approval and marketing authorization for CLL/SLL in China, and the second Bcl-2 inhibitor approved globally. A scientist in a lab conducting research on cell-based therapeutics and biotechnology. Lisaftoclax is an orally administered small-molecule drug designed to treat malignancies by selectively blocking the antiapoptotic protein Bcl-2, thereby restoring the normal apoptosis process in cancer cells. Clinical trials have demonstrated its therapeutic potential in various hematologic malignancies and solid tumors, particularly CLL/SLL, both as a monotherapy and in combinations. Ascentage Pharma Group International (NASDAQ:AAPG) is a clinical-stage biotechnology company that develops therapies for cancers, chronic hepatitis B virus, and age-related diseases in Mainland China. While we acknowledge the potential of AAPG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-07-2025
- Business
- Yahoo
Turkey blocks X's Grok content for alleged insults to Erdogan, religious values
ANKARA (Reuters) -A Turkish court on Wednesday blocked access to some content from Grok, developed by Elon Musk-founded company xAI, after authorities said the chatbot generated responses insulting President Tayyip Erdogan, modern Turkey's founder Mustafa Kemal Ataturk and religious values. Concerns over political bias, hate speech and factual inaccuracy in AI chatbots have mounted since the launch of OpenAI's ChatGPT in 2022, with Grok dropping content accused of antisemitic tropes and praise for Adolf Hitler. Ankara chief prosecutor's office said it launched an investigation, and marked Turkey's first such ban on content from an artificial intelligence tool. Authorities cited violations of laws that make such insults a criminal offence punishable by up to four years in prison. Neither X, nor its owner Elon Musk could immediately be reached for comment. They have not referred to the decision on the platform. Last month, Musk promised an upgrade to Grok, suggesting there was "far too much garbage in any foundation model trained on uncorrected data". Grok, which is integrated into X, reportedly generated offensive content about Erdogan and Ataturk when asked certain questions in Turkish, media said. The Information and Communication Technologies Authority (BTK) adopted the ban after the court order. Transport and Infrastructure Minister Abdulkadir Uraloglu was later cited by broadcaster NTV as saying that Turkey had not yet imposed a total access ban on Grok but that it would do so if necessary, adding Turkish authorities would discuss the issue with X. Yaman Akdeniz, a cyber law expert at Istanbul Bilgi University, said authorities had identified some 50 posts by Grok as the basis for the investigation, ruling on the access ban and removal of certain content to "protect public order". "Turkey has become the first country to impose censorship on Grok," he said on X. Turkey has in recent years significantly increased oversight on social media platforms and online streaming services, passing laws to give authorities more control over content, detaining or arresting individuals for posts, launching probes into companies and limiting or blocking access to certain sites. Critics say the law is frequently used to stifle dissent, while the government maintains it is necessary to protect the dignity of the office.
Time of India
09-07-2025
- Business
- Time of India
Grok AI blocked in Turkey for insulting President Erdogan — Elon Musk's chatbot sparks outrage, faces first national ban
Turkey has imposed a nationwide ban on access to the Grok AI chatbot, developed by Elon Musk's xAI and integrated into the X platform (formerly Twitter). The move follows allegations that the chatbot produced responses considered offensive towards President Recep Tayyip Erdogan. The ban was enforced after a Turkish court issued an order, citing local laws against insulting the head of state. The country's Information and Communication Technologies Authority (BTK) carried out the implementation of the ban. As per Turkish Penal Code provisions, publicly insulting the president is a criminal offense, punishable by up to four years in prison. Court order cites offense under Turkish penal code The legal action was prompted by Grok's responses to user prompts in the Turkish language. According to local media reports, the chatbot's replies were interpreted as derogatory towards President Erdogan. These responses, now circulating on social media, became central to the court's decision to restrict Turkish law, speech considered insulting to the president is treated as a serious crime. The court ruling, therefore, provided grounds for the BTK to act swiftly and block access to the chatbot nationwide. First official ban of an AI tool in Turkey This development marks the first time Turkey has officially banned an AI tool on legal and political grounds. While social media platforms and digital content have faced scrutiny in the past, this instance highlights a growing focus on AI-generated material and its compliance with national laws. The incident also places Turkey among the first countries to take judicial action against artificial intelligence tools based on political sensitivity, setting a precedent in tech policy enforcement. Grok's history of content-related controversies Since its launch, Grok has faced repeated criticism for generating inappropriate and controversial content. Developed by xAI as a direct competitor to OpenAI's ChatGPT, Grok previously drew backlash over outputs that included antisemitic language and remarks appearing sympathetic to historical dictators, including Adolf Hitler. Despite these concerns and now a national ban in Turkey, neither Elon Musk nor the platform X has issued a public response regarding the recent developments. Turkey's ban on Grok reflects rising global tensions over how AI platforms handle political speech, legality, and national boundaries. To stay updated on the stories that are going viral follow Indiatimes Trending.
Bangkok Post
09-07-2025
- Business
- Bangkok Post
Turkey blocks Grok AI for ‘insulting' content
ANKARA - A Turkish court has blocked access to some content from Grok, the AI chatbot linked to the Elon Musk-owned X social media network, after authorities said it generated responses insulting President Erdogan, modern Turkey's founder Mustafa Kemal Ataturk and religious values. Concerns over political bias, hate speech and factual inaccuracy in AI chatbots have mounted since the launch of ChatGPT in 2022, with Grok reportedly producing content accused of antisemitic tropes and praise for Adolf Hitler. The Ankara chief prosecutor's office said on Wednesday that it had launched an investigation that led to Turkey's first such ban on content from an artificial intelligence tool. Authorities cited violations of laws that make such insults a criminal offence punishable by up to four years in prison. Neither X nor Musk could be reached immediately for comment. They have not referred to the decision on the platform. Last month, Musk promised an upgrade to Grok, suggesting there was 'far too much garbage in any foundation model trained on uncorrected data'. Grok, which is integrated into X, reportedly generated offensive content about Erdogan and Ataturk when asked certain questions in Turkish, media said. The Information and Communication Technologies Authority (BTK) adopted the ban after the court order. Yaman Akdeniz, a cyber law expert at Istanbul Bilgi University, said authorities had identified some 50 posts by Grok as the basis for the investigation, ruling on the access ban and removal of certain content to 'protect public order'. 'Turkey has become the first country to impose censorship on Grok,' he said on X. Turkey has in recent years significantly increased oversight on social media platforms and online streaming services, passing laws to give authorities more control over content, detaining or arresting individuals for posts, launching probes into companies and limiting or blocking access to certain sites. Critics say the law is frequently used to stifle dissent, while the government maintains it is necessary to protect the dignity of the office.
Al Etihad
08-07-2025
- Business
- Al Etihad
Emirates Drug Establishment approves world's first oral therapy for immune thrombocytopenia
8 July 2025 14:37 ABU DHABI (WAM) The Emirates Drug Establishment (EDE) has granted official approval for Rilzabrutinib, the first oral Bruton's tyrosine kinase (BTK) inhibitor to be authorised in the country for the treatment of Immune Thrombocytopenia (ITP), a rare autoimmune disorder that affects approximately 2 to 5 individuals per 100,000 people this landmark approval, the UAE becomes the first country in the world to authorise this innovative medication, reflecting the nation's global leadership in accelerating access to advanced treatments and addressing critical medical approval of Rilzabrutinib in the UAE represents a major step forward, offering patients with ITP early access to a pioneering therapeutic solution that contributes to a faster treatment journey and a tangible improvement in quality of decision aligns with the UAE's strategic commitment to ensuring the availability of high-efficacy, globally benchmarked treatments in line with the highest international standards and by global pharmaceutical and healthcare company Sanofi, Rilzabrutinib represents a breakthrough in restoring immune system balance by targeting the underlying cause of increasing platelet counts, the treatment addresses both the symptoms and root causes of the condition. Clinical studies have demonstrated promising outcomes, with patients reporting substantial improvement in health Fatima Al Kaabi, Director-General of the Emirates Drug Establishment, stated, 'The UAE is committed to providing access to the world's latest therapeutic innovations and further promoting its position as a regional hub for pharmaceutical excellence. With Rilzabrutinib getting approved, we take another step further in achieving our strategy aimed at enhancing national pharmaceutical security, implementing advanced treatment protocols, and streamlining regulatory frameworks in collaboration with international partners.'Dr. Al Kaabi emphasised that the milestone demonstrates the effectiveness of the UAE's proactive healthcare policies and flexible regulatory systems in fostering innovation and facilitating patient access to advanced medications.'The Emirates Drug Establishment will spare no effort to accelerate regulatory procedures, and strengthen global partnerships,' she said. 'This further solidifies the UAE's role as a regional centre for pharmaceutical innovation.'She added, 'Granting approval for Rilzabrutinib reaffirms the Establishment's commitment to fast-tracking access to transformative therapies that create significant impact, particularly in the treatment of rare and chronic diseases. EDE will continue to adopt a proactive, innovation-driven approach, fuelled by international collaboration, to ensure that safe, effective therapeutic options are available across the country in accordance with the highest global standards. Our goal is to enhance the UAE's health system preparedness in an era of rapid scientific progress.' For her part, Preeti Futnani, MCO Lead and General Manager, Specialty Care for KSA & Gulf Countries at Sanofi, said, 'We are honoured to collaborate with the Emirates Drug Establishment to bring this groundbreaking treatment to patients in the UAE living with Immune Thrombocytopenia. The approval of Rilzabrutinib demonstrates our shared commitment to placing patients at the centre of our mission and delivering cutting-edge solutions that address some of the most pressing unmet medical needs.'
